Présentation de l'entreprise
Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical entity focused on the development of orally bioavailable small molecule therapeutic products intended for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction within the Israel market. The company functions within the broader Healthcare sector and specifically targets the Biotechnology industry, where it engages in high-risk, high-reward research and development activities rather than established commercial manufacturing. With a total market capitalization of $7.23M and a reported revenue of $405,000, the organization maintains a minimal operational footprint supported by just five employees. These valuation and revenue figures indicate that the company is a micro-cap entity in the early stages of its commercial lifecycle, where the primary value driver is the potential success of its lead drug candidate, Piclidenoson, rather than current cash flow generation from sales.
Santé financière
The company reports a trailing twelve-month revenue of $405,000 against a net income loss of $-9,828,000 and an EBITDA of $-9,926,000, revealing a cost structure characterized by significant operating expenses that vastly outweigh current income generation. This substantial gap between revenue and net income indicates that the business is currently burning through capital to fund its clinical trials and research activities rather than deriving profitability from its product portfolio. Free cash flow stands at $-4,985,750, which signifies a negative financial flexibility requiring continuous external financing to sustain operations and prevent liquidity shortfalls. The gross margin is reported at 100.0%, suggesting a cost of goods sold structure that aligns with a pre-revenue or low-volume clinical stage where inventory costs are negligible, while the operating margin of -2488.7% and profit margin of 0.0% reflect the heavy investment phase and lack of net earnings. The balance sheet holds $8.54M in cash against only $71,000 in debt, resulting in a debt-to-equity ratio of 1.27, which presents a complex picture of a firm with substantial liquid assets relative to liabilities but high leverage metrics due to the accounting treatment of equity in loss-making entities. The current ratio of 3.46 indicates a strong short-term liquidity position, as the company holds significantly more current assets than current liabilities, providing a buffer against immediate obligations. However, the return on equity of -178.2% and return on assets of -66.7% reveal that management effectiveness, measured by traditional return metrics, is currently negative as the company destroys shareholder value through operational losses rather than generating returns on its capital base.
Évaluation de la valorisation
The trailing P/E ratio is listed as N/A due to the lack of positive earnings, while the forward P/E stands at -4.22, implying that the market anticipates continued negative earnings in the near term rather than an immediate turnaround. The price-to-book ratio of 1.44 suggests that the market values the company at a 44% premium over its tangible book value, a common characteristic for biotech firms where intellectual property and pipeline potential are valued above historical asset records. The price-to-sales ratio of 17.85 and the EV/EBITDA of -0.48 serve as alternative valuation metrics that highlight the high multiple paid for revenue given the absence of profitability, indicating that investors are pricing in significant future growth expectations or asset value not reflected in current financial statements. The stock has traded within a 52-week range between a low of $2.95 and a high of $36.40, meaning the current valuation sits at the lower end of its historical volatility band relative to the absolute high. A beta of -0.10 is an anomalous metric for a biotechnology stock, suggesting an inverse correlation with the broader market or extreme idiosyncratic risk that causes the stock price to move counter to general market trends, rather than exhibiting the typical positive correlation expected in the sector.
Growth & Income
Revenue growth year-over-year has declined by -43.3%, while earnings growth is marked as N/A, indicating that the company has not yet achieved consistent profitability to calculate meaningful earnings expansion rates. The decline in revenue suggests a contraction in sales or a transition period following the cessation of certain revenue streams, which is typical for clinical-stage companies as they pivot from initial commercialization to later-stage development. As the company does not pay a dividend, with a dividend yield of N/A and a payout ratio of 0.0%, it retains all generated cash to fund its research and development pipeline instead of distributing income to shareholders. Consequently, the overall growth and income profile is defined by negative cash flow and revenue contraction in the short term, relying entirely on the successful advancement of its drug candidates to shift the trajectory toward future profitability and potential shareholder returns.